Nucleoside analogue therapy allows safe, long-term suppression of hepatitis B virus (HBV) and is a major milestone in the treatment of chronic hepatitis B. Entecavir has recently been approved by the U.S. Food and Drug Administration and is not only more potent than lamivudine and adefovir, but it is also associated with a very low rate of drug resistance. Peginterferon, which has been shown to be more potent than conventional interferon, has recently been licensed in Europe and the United States. Despite these advances, however, the clinician still faces several challenges in treating this relatively complex disorder. Controversies and unresolved issues remain, including the question of whether the thresholds for alanine aminotransferase and HBV DNA levels recommended in the published treatment guidelines are too restrictive. Another complication is the differing levels of sensitivity and dynamic range of the assays for serum HBV DNA. Finite courses of treatment are associated with low rates of virologic response, but drug resistance occurs when nucleoside analogue monotherapy is used long term. The role for combination therapy remains unclear. Much has been accomplished over the past decade, but much remains to be done.
The treatment of chronic hepatitis B has undergone major changes in the last 5 years and continues to evolve. Five drugs are now licensed to treat this disorder-conventional interferon alfa-2b (IFN-a 2b), peginterferon alfa-2a, lamivudine, adefovir, and entecavir. Each of these agents has been found to demonstrate efficacy against both hepatitis B e antigen (HBeAg)-positive and HBeAg-negative chronic hepatitis B. Despite the number of new drugs, however, the clinician still faces an array of challenges related to the complexity of host-virus relationships in chronic infection with hepatitis B virus (HBV), a lack of standardization in assays to measure HBV DNA, and the limited efficacy of current treatment regimens. This article emphasizes the benefits and limitations of current approaches to treatment and outlines areas that need to be addressed in the future.
GUIDELINES FOR THE MANAGEMENT OF CHRONIC HEPATITIS B
The American Association for the Study of Liver Diseases, the European Association for the Study of the Liver, and the Asian-Pacific Association for the Study of the Liver have each published practice guidelines for the management of chronic hepatitis B. [1] [2] [3] As evidencebased documents, the guidelines provide objectivity and clarity to treatment decisions ( Table 1 ). The recommendations made in these guidelines can be particularly useful for hepatologists and gastroenterologists who may infrequently manage this disorder.
In general, the guidelines of the three organizations are quite similar. The guidelines need to be periodically updated because of unavoidable delays in publication that prevent the incorporation of the most recent data. In addition, because of a paucity of clinical trial data, none of the guidelines includes definitive recommendations for certain patient subgroups, such as those with human immunodeficiency virus (HIV) or hepatitis C virus (HCV) coinfection, HBV carriers undergoing chemotherapy, and pregnant females with chronic hepatitis B.
All of the guidelines stipulate similar thresholds for serum HBV DNA and alanine aminotransferase (ALT) levels, at which point treatment is recommended. HBV DNA levels in excess of 10 5 copies/mL (or approximately 20,000 IU/mL), are suggested as an appropriate threshold for the initiation of treatment for both HBeAg-positive and HBeAg-negative chronic hepatitis B. Only rarely do patients with HBeAgpositive chronic hepatitis B have HBV DNA levels below 10 5 copies/mL, but 30% of patients with HBeAg-negative chronic hepatitis B exhibit HBV DNA levels that occasionally fall below this limit when serial blood samples are tested. 4, 5 The guidelines recommend treatment for patients with ALT levels that are at least twice the upper limit of normal. This recommendation is based on the observation of low rates of sustained virologic response in patients with lower levels of ALT when they are treated with interferon or nucleoside analogues. 6 Nonetheless, these thresholds are arbitrary, and they exclude some patients who might otherwise benefit from therapy. Considering that ALT level varies according to body mass index, gender, and other factors, it has been proposed that the upper range of normal for ALT may be set too high: normal values should not be interpreted to mean that there is no underlying inflammatory change in the liver. 7 The results of a recent study done in China underscore the significance of this statement as it applies to chronic HBV infection. In this study, 183 HBeAg-positive HBV carriers with persistently normal ALT values underwent liver biopsy. Of these patients, 40% had grade 2 inflammation and 35% had stage 2 fibrosis. 8 In view of such concerns, some experts have proposed a modified treatment algorithm that endorses the treatment of patients with lower serum HBV DNA levels and any elevation of ALT.
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EVALUATION OF SERUM HBV DNA The major goal of antiviral treatment of chronic hepatitis B is to reduce serum HBV DNA permanently to the lowest possible level. Polymerase chain reaction (PCR) -based assays are more sensitive than signal amplification and direct hybridization assays, and allow detection of 10 2 or fewer copies of HBV DNA (the lower limit of detection for non-PCR-based assays is 2 to 3 logs higher). The problem with PCR-based assays, however, is that some do not accurately quantify HBV DNA levels at the high end of values. Thus, end point measurements require multiple dilutions, and this increases the expense of the assay considerably.
The range of values over which an assay can accurately quantify serum HBV DNA in a linear fashion is referred to as the dynamic range for that assay. Ideally, this should be as broad as possible, allowing detection of less than 10 genomic copies to several hundred million copies. Unfortunately, the dynamic range of quantification of the available HBV DNA assays varies considerably; none covers the full range of HBV DNA values that can be observed in untreated and treated patients who have chronic HBV infection. 10, 11 The more recently developed real-time PCR assays have the best dynamic range (30 to 10 8 IU/mL) and enable accurate quantification of serum HBV DNA in patients with high-level viral replication without the need for dilution.
Interpretation of the results from these assays is complicated by technical issues. Until recently, most laboratories reported serum HBV DNA values in copies per milliliter, which made cross-comparison of the results of different assays difficult. The World Health Organization has recommended that serum HBV DNA levels now be expressed in international units 15 in this supplement). Under conditions of high levels of viral replication, it is likely that HBV mutations conferring resistance to any of the nucleoside analogues pre-exist; it is considerably less likely, however, that mutations pre-exist that would confer resistance to more than one nucleoside analogue agent. This is why some authorities have suggested that combination nucleoside analogue therapy might be preferable as an initial treatment strategy. 16 Surprisingly, however, lamivudine-resistant HBV has been detected in treatment-naïve patients who received combination therapy with lamivudine and adefovir: resistance occurred in 2% of patients after 52 weeks of therapy 17 and in 19% of patients at treatment week 104 (Glaxo SmithKline, data on file, 2005). Moreover, YMDD mutant HBV was detected in 58% and 70% of patients, respectively, who experienced virologic breakthroughs (defined as 1 log 10 increase in HBV DNA) at the same intervals. These results could be partially attributable to the relatively weak antiviral activity of adefovir against the YMDD mutant HBV. Studies using other combinations are needed before conclusions can be drawn about the utility of multidrug therapy. Combination therapy to prevent resistance also entails additional expense and, in theory, could facilitate the selection of multidrug-resistant HBV. Because of these concerns and the fact that increasingly potent drugs with low resistance profiles are being developed (see Entecavir, below), it seems unlikely that combination therapy will become the standard of care to treat all patients with chronic hepatitis B.
CURRENTLY AVAILABLE ANTIVIRAL DRUGS

Interferon a-2b
Interferon activates intracellular ribonucleases that degrade viral messenger RNA; IFN-a 2b is the only licensed agent that is immunomodulatory. 18 This action of interferon could be operatively important in reducing the amount of the covalently closed circular (ccc) form of HBV DNA (the genomic template for viral transcription), which may explain the loss of hepatitis B surface antigen (HBsAg) that occurs in approximately 5 to 8% of interferon-treated patients. The major disadvantages of interferon are related to its poor tolerability in comparison with nucleoside analogues, to its lower level of HBV DNA suppression, and to its greater cost during a year of treatment ( Table 2) . Flares of ALT may occur during therapy with conventional IFN-a and peginterferon. Although these flares are potentially important in achieving a virologic response, their unpredictability limits antiviral efficacy. 18, 19 Pretreatment HBV DNA level is a predictor of loss of HBeAg or HBeAg seroconversion during treatment with either conventional interferon or peginterferon. 20 In patients who have high levels of viremia (> 30 million copies, or approximately 5.3 million IU/ mL), the magnitude of an ALT flare predicts the likelihood of sustained virologic response. This observation suggests that vigorous cell-mediated immune responses are often required to overcome high levels of viral replication. 19 Peginterferon is more effective than conventional interferon in the treatment of HBV infection, producing reductions in serum HBV DNA level of 3 to 4 logs.
21-24
Whether the increased antiviral efficacy of peginterferon is exclusively a function of a more pronounced effect on viral replication, or whether it may also be influenced by a greater immunomodulatory action cannot be determined from the data currently available. Recent studies have focused almost entirely on its antiviral effects. However, recent analysis of data from a large study of HBeAg-positive patients treated with peginterferon alfa-2a, either alone or in combination with lamivudine, showed that treatment-induced ALT flares occurred more frequently with peginterferon monotherapy and were associated with a higher rate of HBeAg seroconversion. 25 Thus, better understanding of the immunologic action of peginterferon is needed.
One of the limitations in using interferon is that response rates vary according to HBV genotype. This does not appear to be an issue with nucleoside analogue therapy. 26 Early studies on the relationship of HBV genotype to interferon response were limited by small sample sizes. 27 A more convincing relationship between virologic response and genotype has been demonstrated recently in a study involving 266 patients with HBeAgpositive chronic hepatitis B. 22 The trial compared peginterferon alfa-2b monotherapy with interferon used in combination with lamivudine. Patients with genotype A demonstrated the highest rates of HBeAg loss, as compared with the rates associated with genotypes B, C, and D (47, 44, 28 , and 25%, respectively). A second study, involving 814 patients treated with peginterferon alfa-2a, also showed that HBeAg seroconversion occurred more frequently in genotype A patients than in patients with the other genotypes (52, 30, 31 , and 22%, respectively). These studies confirm and extend the findings from earlier studies in HBeAg-positive and HBeAg-negative patients, and indicate that patients with genotype A respond far more frequently than do those with genotypes C and D. These studies may be helpful in predicting the level of response that may be anticipated among a growing population of Asian Americans who often carry the less-responsive genotype C. 28 Nucleoside Analogues Nucleoside analogues have excellent oral bioavailability, a good safety record, and antiviral efficacy comparable to that observed with IFN-a 2b. They are also considerably less expensive than interferon when given for 48 to 52 weeks. These drugs have proved to be particularly useful in the management of patients with decompensated cirrhosis, in whom even low doses of interferon can lead to worsening liver failure and severe infections. Table 2 lists the available nucleoside analogues and the advantages and limitations associated with their use.
Nucleoside analogues prevent the incorporation of natural nucleosides into HBV DNA and act as competitive inhibitors of the viral reverse transcriptase and DNA polymerase. Because nucleoside analogues partially and reversibly suppress viral replication, they have to be given for more than 1 year in most cases to achieve maximal efficacy. Unfortunately, drug resistance occurs with prolonged monotherapy (Table 3) . 13, 29, 30 Salvage therapy with another nucleoside or nucleotide analogue may be possible if the two drugs do not share similar resistance sites. Nucleoside analogues have other limitations. In particular, clearance of cccDNA has been difficult to demonstrate, and unlike interferon, nucleoside analogues rarely produce HBsAg clearance after 1 year of treatment.
LAMIVUDINE
Lamivudine is a relatively potent inhibitor of viral replication and is extremely well tolerated. In clinical trials, a 1-year course of lamivudine suppressed viral replication and resulted in histologic improvement. 31 In one study, HBeAg seroconversion and HBeAg loss occurred in 17% and 32% of patients, respectively. 32 A 2-year course of lamivudine proved to be more effective than a 1-year course, increasing the rate of HBeAg seroconversion from 17% at 1 year to 27% at 2 years. 33 Extending treatment beyond 1 year, however, has been associated with incremental increases in viral resistance, up to approximately 40% at 2 years. The longer the treatment is continued, the more frequently resistance is seen (65% at 5 years). 13 Resistance is even more commonly encountered in patients coinfected with HIV type 1 (HIV-1; 90% at 4 years). 34 Lamivudine maintenance therapy has been associated with improvement in liver histology, including improvement in bridging fibrosis and cirrhosis, when the treatment is extended beyond 52 weeks. A large, doubleblind, placebo-controlled study of long-term lamivudine therapy versus placebo convincingly demonstrated that TREATMENT OF HEPATITIS B/PERRILLO prolonged treatment can prevent disease progression and reduce the incidence of hepatocellular carcinoma.
14 In this study, lamivudine-treated patients with YMDD mutant HBV had an intermediate response, compared with that observed in patients with wild-type HBV and in those given placebo. For patients in advanced stages of chronic hepatitis B, the use of drugs that can achieve greater viral suppression with lower rates of resistance would be expected to yield even greater therapeutic benefit.
ADEFOVIR DIPIVOXIL
Adefovir dipivoxil was approved for the treatment of HBeAg-positive and HBeAg-negative chronic hepatitis B based on the findings from randomized, controlled clinical trials in the United States, Europe, and Asia. 35, 36 In these studies, 48 weeks of adefovir treatment resulted in median serum HBV DNA reductions of 3.52 and 3.91 log 10 copies in HBeAg-positive and HBeAg-negative disease, respectively. The rate of HBeAg seroconversion (12%) and HBeAg loss (24%) after 48 weeks of treatment was slightly lower than that achieved with 52 weeks of lamivudine. A progressive increase in the frequency of HBeAg seroconversion and nondetectability of HBV DNA by PCR has been documented during 4 years of adefovir treatment. [35] [36] [37] [38] The degree of HBV DNA suppression with adefovir is less than that achieved with lamivudine, and the two drugs differ greatly in their resistance profiles. Point mutations (A181V, N236T) in the B and D domains, respectively, of the HBV polymerase gene affect HBV susceptibility to adefovir, but the cumulative incidence of adefovir resistance is 0% at 48 weeks of treatment, 3% at year 2, 6% at year 3, and 18% at year 4.
38,39 HBV isolates with the N236T mutation have remained susceptible to lamivudine and appear to be sensitive to entecavir (and telbivudine) in vitro. 40 The low rate of resistance with prolonged adefovir therapy has made adefovir particularly suitable as first-line therapy in HBeAg-negative chronic hepatitis B because of the need for long-term treatment to prevent relapse. Adefovir is clinically and virologically effective in patients with lamivudine-resistant HBV. This has been demonstrated in patients with clinically stable disease, decompensated cirrhosis, and recurrent hepatitis B after liver transplantation. 41, 42 Adefovir has been shown to be effective when used alone or in combination with lamivudine maintenance therapy. In one study, 37% of patients with lamivudine-resistant virus experienced serious ALT flares when switched to adefovir monotherapy. 42 These data have led many experts to advise that patients with serious underlying liver disease be maintained on lamivudine when adefovir is used as salvage therapy, but this remains controversial. Adefovir has the disadvantage of being potentially nephrotoxic, and dose reductions may be necessary in patients likely to develop compromised renal function. 43 
ENTECAVIR
Entecavir is a deoxyguanine nucleoside analogue that selectively inhibits HBV replication. This drug has recently been approved by the FDA and the European health authorities for use in both HBeAg-positive and HBeAg-negative chronic hepatitis B. Entecavir inhibits HBV replication by affecting both the priming of HBV DNA polymerase and the synthesis of the first and second strands of HBV DNA. It has been shown to be effective against both wild-type and lamivudineresistant HBV.
A dose of entecavir 0.5 mg given daily for 24 weeks reduced HBV DNA by an additional 1.28 log 10 copies/mL over that achieved with lamivudine in treatment-naïve HBeAg-positive patients. 44 In HBeAgpositive chronic hepatitis B, entecavir caused a 1.5 log 10 greater reduction in serum HBV DNA than did lamivudine after 48 weeks of treatment, but the rates of HBeAg seroconversion were comparable, at 21 and 18%, respectively. 45 In HBeAg-negative chronic hepatitis B, entecavir resulted in a greater percentage of patients becoming HBV DNA negative by PCR when compared with lamivudine (91 versus 73%, respectively). 46 Phase III clinical trials used a 0.5-mg dose of entecavir in nucleoside analogue-naïve patients with either HBeAgpositive or HBeAg-negative disease, whereas the 1-mg dose of entecavir was found to be the most effective in patients with lamivudine resistance. 29 Entecavir resistance is rare and thus far has only been reported in lamivudine-resistant patients. 47 Phenotypic resistance is relatively mild (approximately 8-fold) in association with lamivudine-resistant virus alone; this increases to more than 100-fold when one or more unique nucleotide substitutions in the polymerase gene are added to the lamivudine-resistant mutations (Table 4) . 48 Entecavir-resistant HBV remains susceptible to adefovir or tenofovir but not to lamivudine. Entecavir appears to be the most promising of the licensed nucleoside analogues. However, its use at this time may be limited by its relatively high cost (approximately four times the cost of lamivudine and 30% more than adefovir) and the absence of long-term safety and efficacy data.
Drugs Not Specifically Licensed for HBV
Two drugs licensed for use in HIV infection also have activity against HBV. The information on these drugs is limited to that from small clinical trials that lacked a rigid study design.
EMTRICITABINE
Emtricitabine (FTC) is a fluorinated cytosine analogue that inhibits HBV DNA polymerase and HIV reverse transcriptase. This drug is very closely related structurally to lamivudine, differing by the attachment of one fluorine atom, and it therefore shares similar mutational sites and associated rate of resistance. Emtricitabine is currently licensed in the United States and other parts of the world for HIV-1 infection.
Clinical investigation showed that 48 weeks of treatment with emtricitabine 200 mg daily reduced serum HBV DNA by a median of 3 log 10 copies/mL and significantly improved liver histology. 49 Studies in HIV-1-coinfected patients showed degrees of suppression similar to those noted in patients with HBV infection alone. 50 The incidence of YMDD mutations in patients receiving emtricitabine 200 mg daily is 12% at week 48 and 19% at week 96. 49, 51 In a recently reported double-blind, randomized trial, equivalent proportions of patients demonstrated HBeAg seroconversion (12%) and resistance (12.6%) during a 48-week course of treatment. 49 Based on these findings, it is unlikely that emtricitabine will play a significant role in the management of chronic hepatitis B other than in patients with combined HIV-1 infection.
TENOFOVIR DISOPROXIL FUMARATE
Tenofovir is an acyclic nucleotide inhibitor of HBV polymerase and HIV reverse transcriptase that has close chemical similarity to adefovir dipivoxil. It has been licensed for the treatment of HIV-1 infection. Its antiviral activity against HBV is reported to be greater than that associated with adefovir 10 mg in lamivudineresistant patients. 52 Reports of therapeutic efficacy have largely come from small clinical trials in patients with lamivudine-resistant HBV, in whom 3-to 5-log 10 reductions in serum HBV DNA have been observed after 1 year of treatment. [52] [53] [54] [55] The N236T mutation that confers resistance to adefovir is somewhat sensitive to tenofovir. Despite the possibly greater antiviral potency over that of adefovir, no data from large-scale studies of tenofovir for chronic hepatitis B are yet available. The FDA recently approved a combination formulation of tenofovir and emtricitabine for use in HIV infection. This combination drug, in theory, could be useful because HBV that is resistant to emtricitabine remains susceptible to tenofovir, and tenofovir-resistant HBV remains susceptible to emtricitabine.
Combination Therapy COMBINATION NUCLEOSIDE ANALOGUE TREATMENT
In addition to reducing the rate of drug resistance, combination nucleoside analogue therapy may also have greater antiviral efficacy. In vitro data and studies in the woodchuck model of hepatitis B have shown that combinations of nucleoside analogues lead to greater suppression of HBV replication than does TREATMENT OF HEPATITIS B/PERRILLO monotherapy. 56 Additive effects on viral replication could have specific benefit for individuals who have high viral levels or hepatic decompensation, in whom there is a need for more immediate stabilization of disease. These considerations have led to several clinical trials in humans. Surprisingly, the results of early clinical trials of combination therapy in treatment-naïve patients with HBeAg-positive chronic hepatitis B have shown that the combination of two nucleoside analogues (telbivudine and lamivudine) or the combination of a nucleoside analogue with a nucleotide analogue (lamivudine and adefovir) does not result in greater virologic response during the first 1 or 2 years of treatment. 30, 57, 58 The reasons for the lack of apparent additive effect in these studies remain unexplained. The possibility exists that nucleoside analogues taken in combination sterically inhibit each other from binding to the HBV DNA polymerase, or that they compete for phosphorylation enzymes (kinases) required for drug activation. Whatever the reason, the results of these studies indicate that not all combinations will have additive efficacy, and that adding a less potent drug to a more potent one may actually subvert the effectiveness of the more potent drug. More information is needed on potential drug interactions so that optimal combination regimens can be devised.
COMBINATION INTERFERON AND NUCLEOSIDE
ANALOGUE THERAPY
From a conceptual standpoint, the combination of interferon with a nucleoside analogue should prove to be more effective than either drug alone because these agents have different mechanisms of action. Combination therapy might also allow for a shorter course of therapy for the nucleoside analogue, thereby reducing the risk of viral resistance. To date, three large multicenter studies have evaluated the combination of peginterferon and lamivudine; all three studies compared combination therapy with interferon alone, and two of the studies compared the combination with lamivudine monotherapy. [22] [23] [24] Despite the demonstration of additive viral suppression during treatment in all three studies, in no study was a higher rate of sustained virologic response observed in the combination arm as opposed to the peginterferon-alone arm. As disappointing as this may appear, all three studies provided proof of concept that peginterferon combined with lamivudine results in greater viral suppression, and the two studies in which combination therapy was compared with lamivudine monotherapy demonstrated a lower rate of lamivudine resistance in the combination arms.
It is possible that different treatment schedules could affect the results. In a recent study from Hong Kong, for example, a higher rate of sustained virologic response (36 versus 14%) was found in HBeAg-positive patients treated with a combination of pegylated IFN-a 2b plus lamivudine than in those receiving lamivudine alone. 59 This study differed in design, however, from the three studies described above in that the peginterferon was given in an 8-week induction period before the initiation of lamivudine, because of the theoretical concepts that peginterferon enhances immune clearance of HBV, including cccDNA, and that adding lamivudine at a later time would prevent reinfection of hepatocytes.
SUMMARY: BENEFITS AND LIMITATIONS OF CURRENT APPROACHES TO TREATMENT
The treatment of chronic hepatitis B continues to evolve. Unprecedented advances have occurred during the last 5 years, providing the foundation for evidence-based treatment guidelines. Although these are helpful in systemizing the approach to care, a substantial number of patients fall outside of the current biochemical and virologic thresholds in these guidelines that define treatment initiation. In addition, definitive recommendations are lacking for several patient groups and clinical situations for which the evidence is insufficient. Assays are now available that reliably measure fewer than 100 copies (or 10 IU/mL) of serum HBV DNA. Monitoring remains relatively complex, however, because commercially available test methods have differing levels of sensitivity and dynamic range.
Programs for the development of nucleoside analogues are moving toward the design of drugs that demonstrate increased antiviral potency and low rates of resistance. These drugs will still need to be administered over the long term, which has the potential to lead to selection for drug-resistant mutants. Combination nucleoside analogue therapy is likely to reduce the problem related to resistance, but this approach may not be practical or necessary for all patients, particularly as increasingly potent drugs with low resistance profiles continue to be developed. Combination drug therapy should ideally demonstrate additive antiviral effects, but early studies in this regard have been disappointing. Data demonstrating the enhanced potency of peginterferon now provide a reason to re-evaluate the role for interferon in the treatment of chronic hepatitis B; adverse effects, however, are likely to limit its use, and certain genotypes (e.g., C and D) appear to be associated with suboptimal response. A great leap forward for this field would be the development of immunologic modifiers exhibiting better tolerability profiles and more predictable efficacy than interferon. The same could potentially be said of other drugs that reduce serum HBV DNA independently of inhibition of viral DNA polymerase. In short, safe and easily affordable drugs that can be given for finite courses of treatment and produce a high rate of durable virologic response are yet to be developed. Much has been accomplished in the therapy of hepatitis B during the last several years, but much remains to be done. 
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